Longevity news · updated July 15, 2026
Dated, sourced updates on longevity clinics, devices and research. Each one explains what changed and whether it should change what you buy, book or skip.
Neko Health raised $700 million on July 15 to fund U.S. expansion. Its New York clinic is still listed as coming in 2026, with a waitlist and no published U.S. price. The funding may speed expansion, but it does not change what U.S. buyers can book today or strengthen the clinical evidence.
Independent coverage reported Fountain Life’s new BASE membership at $595 per year, far below its five-figure APEX membership. BASE includes more than 100 blood biomarkers, a DEXA scan, clinician-guided review and digital tracking, but availability and any extra charges still need confirmation. Ask for the current written tier comparison and a complete first-year price before joining.
The FDA closed its warning to WHOOP on June 23, 2026 after the company changed how Blood Pressure Insights is presented. The feature remains a general-wellness estimate, not a medical blood-pressure reading. Use a validated upper-arm cuff for clinical decisions.
Oura Ring 5 began shipping June 4, 2026 at $399, with a thinner design and a claimed six to nine days of battery life. Its new blood-pressure signal is not an FDA-cleared monitor. Treat it as a trend flag until independent clinical validation is available, and use a validated cuff for actual blood-pressure readings.
On June 12, 2026, the FDA cleared the Dexcom Stelo Glucose Biosensor System for over-the-counter use by people ages two and older who do not use insulin, expanding the original March 2024 adult clearance to pediatric users. The hardware is the same: a 15-day wearable sensor delivering 15-minute glucose readings via smartphone, with adults required as caregivers for child users. The clearance is an access decision, not a shift in evidence: the label excludes insulin-dependent users and does not endorse Stelo as a long-term health monitor for metabolically healthy children. The buyer logic that applied to adults, a short-window audit rather than an open subscription, applies at least as much here.
Context, not news: the FDA cleared Dexcom Stelo in March 2024 as the first over-the-counter CGM for adults who do not use insulin, including non-diabetics who want diet-and-exercise feedback. Two years on, access is wide but the label is unchanged. It still tells users not to make medical decisions from the output without a clinician, and a useful two-week audit is not the same thing as a forever subscription.
The FDA safety communication is the line to remember: it has not authorized, cleared or approved any smartwatch or smart ring that measures or estimates blood glucose by itself. A watch can display data from a real CGM; it is not the sensor.
Independent spectrometer testing keeps landing the same way: the irradiance brands advertise – measured on cheap solar meters – runs two to three times the real figure, and almost no panel clears ~90 mW/cm² at six inches when measured properly. Buy on the measured number, at a stated distance, not the box.
The FDA’s 2025 guidance to clinicians ties hyperbaric oxygen devices to fires causing serious injuries and deaths, and flags centers promoting unapproved aging and longevity uses. HBOT is not cleared for aging-reversal claims – and the home soft-shell at 1.3 ATA is not the 2.0 ATA dose the longevity studies used.
The Agewell Briefing
A sourced weekly read on longevity products, clinics and research, with a clear answer on what is worth trying.
One email a week. Unsubscribe with one click.